Antidepressant

Comparison of the effectiveness of different classes of antidepressants with placebo and with other forms of treatment like psychosocial interventions in women with postpartum depression Introduction .Depression is one of the psychological disorders that influence 15-25 % of adults in United States every year. Women are twice as likely as men to experience symptoms of depression. In women, most common period of occurrence of depression is between 18-44 years and this happens to be the prime childbearing

effects of current antidepressants have forced researchers to look for new and safer drugs (1, 2) with rapid onset and longer acting times. Results obtained in recent years have been encouraging especially with ketamine a global NMDAR antagonist. The antidepressant-like activity of ketamine has been shown in many preclinical studies (1–7). A single non-anesthetic dose of ketamine reversed the symptoms of major depression (MDD) under clinical conditions (8). The antidepressant effects of ketamine

Depression is a chronic, recurrent psychiatric disorder affecting nearly 21% of the world population (Gu et al., 2014; Lai et al., 2014). According to the world health organization (WHO) reports, it will become the 4th leading cause of disability worldwide by the year 2020 (WHO, 2001; Wang et al., 2013). The monoamine theory states that the brain neurotransmitters such as 5-Hydroxytyrptamine (5-HT), Norepinephrine (NE), and Dopamine (DA) assume to play a key role in the pathophysiology of depression

research question is based on finding the best treatment available for depression. (P) Among depressed women (I) does combining ECT and antidepressants (C) or using antidepressant alone (O) reduce the rate of readmission (T) in 3 months? Research question: Among depressed women does combing ECT and antidepressant reduce the rate of readmission better than using antidepressant alone in a period of 3

Vilazodone is a novel dual-acting serotonergic antidepressant. Its dual mechanistic approach combines two mechanisms in a single drug, namely serotonin transporter (SERT) inhibition with 5HT1A receptor partial agonist actions. Hence, vilazodone is called a serotonin partial agonist reuptake inhibitor (SPARI). This combined activity releases serotonin across the brain’s serotonergic pathways specifically by inhibiting the serotonin transporter, similar to a selective serotonin reuptake inhibitor

of getting over your depression within a matter of a few weeks. However, without these treatments Eugene, you may get better immediately, but just keep in mind that your depression could take a few months to a few years. However though, taking antidepressants do not quite work for depressive episodes like aspirin would for a headache. It may take anywhere from 2 to

Antidepressant medication and brief psychotherapy programs are effective. Antidepressant can be very effective form of treatment for moderate to severe depression. However; it is not the first line treatment. As the number of people with mental illness is rapidly increasing across the world a number of antidepressant synthetic chemicals are being used for the treatment of depressive disorders, are believed

very common disorder until the use of legal and illegal drugs. According to Whitaker, “… 60 percent of those with a bipolar diagnosis said they had initially fallen ill with major depression and had turned bipolar after exposure to an antidepressant” (181). Antidepressants are used to treat bipolar disorder, but it seems that instead of treating it, it makes it worse. There was one time that bipolar patients were treated with lithium. According to Whitaker, Guy Goodwin, a Scottish psychiatrist concluded

The SSRIs are advantageous due to their ease of dosing and low toxicity in overdose. They are preferable over the other classes of antidepressants when treating minors and are also the first-line medications for late-onset depression. The common adverse effects of SSRIs include sexual dysfunction, gastrointestinal upset, as well as changes in energy level. The SSRIs are relatively unproblematic in patients with cardiac disease, as its agents does not affect blood pressure, heart rate, cardiac conduction

numerous side effects of current antidepressants have forced researchers to look for new and safer drugs (1, 2) with rapid onset and longer acting times. Results obtained in recent years have been encouraging, especially with ketamine a global NMDAR antagonist. The antidepressant-like activity of ketamine has been shown in many preclinical studies (1–7). A single non-anesthetic dose of ketamine reversed the symptoms of clinical major depression (MDD) (8). The antidepressant effects of ketamine were also